



ACCADEMIA NAZIONALE DI MEDICINA

17th MEET THE PROFESSOR

Advanced International Breast Cancer Course (AIBCC)

For information
www.accmed.org



GYMNASIVM
MNIVM DISCIPLINA

PRINCIPE PASCHALI CICONIA
PRÆSID IOANNE SVPERANTIO EQ·ET FEDERICO
REFORMATORIBVS IO·FRANC·PRIOLO DOCTORE, ZACHA
LEONARDO DONATO EQ· INSTAVRATVM ANNO M

Aims

Mortality from breast cancer is declining in most countries thanks to effective screening programs, early diagnosis, molecular characterization of the different subtypes and biology-driven treatments. A multidisciplinary management of breast cancer patients is therefore the key to success and a breast multidisciplinary team should include - besides the “classic” clinical specialties - pathologists, molecular biologists and geneticists. Furthermore, the availability of multiple diagnostic and therapeutic choices, the increasing costs of new technologies and drugs and the issue of sustainability represent a new challenge for socially-responsible clinicians. With this goal in mind, the Programme includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes and issues of sustainability and drug access across countries.

Addressed to

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses.

» *Live Webinar*

Thursday, September 30th

14.30 **On-line registration of participants**

14.45 **Introduction to the Conference**

Pier Franco Conte, Gabriel N. Hortobagyi,
Valentina Guarneri, Philip Poortmans

SESSION I

Chairpersons: Hesham Ahmed Gaballah Elghazaly, Pierfranco Conte

15.20 **Obesity and cancer**

Roberto Vettor

15.20 **Management of women BRCA1/2
and other predisposition gene mutations**

Shani Paluch-Shimon

15.40 **Axillary dissection: still an option?**

Elefterios Mamounas

16.00 **Hot topics in breast cancer RT**

Philip Poortmans

16.20 **Clinical impact of genomics in BC**

Alex Prat

16.40 **PIK3CA testing: from technical aspects to clinical application**

Sybille Loibl

17.00 **Prognostic signatures to guide treatment decision**

Gabriel N. Hortobagyi

17.20 **Q&A**

17.30 **Adjourn**

Friday, October 1st

SESSION II

Chairpersons: Jacek Jassem, Valentina Guarneri

- 14.30 **Adjuvant CDK4/6i for HR+ disease: reconciling data from randomized trials**
Valentina Guarneri
- 14.50 **Early BRCAm tumors: PARPi are coming!**
Pier Franco Conte
- 15.10 **Neoadjuvant therapy for early breast cancer: beyond the pCR dogma**
Pier Franco Conte
- 15.30 **Immunotherapy for early TNBC: hopes and hypes**
Hope Rugo
- 15.50 **Q&A**
- 16.10 **Antibody Drug Conjugates for BC**
Frederik Marmè
- 16.30 **Targeting unconventional pathways in Luminal BC**
Maria Vittoria Dieci
- 16.50 **Treatment algorithm for HR+/HER2- ABC**
Stephen Johnston
- 17.10 **Treatment algorithm for HER2+ ABC**
Sandra M. Swain
- 17.30 **Treatment algorithm and new options for TN ABC**
Miguel Martin
- 17.50 **Q&A**
- 18.10 **Adjourn**

CME

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31- 324301): **9 CME points**.

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

The credit certification for the webinar is subject to:

- Professions/specializations should correspond to those which have been accredited for CME
- attendance at the 100% of the async distance learning and webinar live on the platform fad.accmed.org;
- the completion of the Meeting evaluation online form;
- completion of the final test (at least 75% of correct answers). 5 attempts admitted.

The test and the meeting evaluation form must be completed within 3 days from the end of the event.

Teaching method

The LIVE Webinar will allow participants to attend to AIBCC 2021 from anywhere in the world.

The LIVE Webinar, with the participation of speakers connected from various countries, is addressed to both Italian and foreign participants. The official language of the course is English. No simultaneous translation will be provided.

To follow the webinar, participants will need a good quality internet connection and a device (PC, Smartphone, Tablet) capable of running a recent Internet browser (e.g. any updated version of Chrome or Firefox).

» *In-Class Course*

Thursday, September 30th

14.45 Introduction to the Conference

Pier Franco Conte, Gabriel N. Hortobagyi, Valentina Guarneri,
Philip Poortmans

The speakers will be connected by various countries

SESSION I

Chairpersons: Hesham Ahmed Gaballah Elghazaly, Pierfranco Conte

15.20 Obesity and cancer

Roberto Vettor

**15.20 Management of women BRCA1/2
and other predisposition gene mutations**

Shani Paluch-Shimon

15.40 Axillary dissection: still an option?

Elefterios Mamounas

16.00 Hot topics in breast cancer RT

Philip Poortmans

16.20 Clinical impact of genomics in BC

Alex Prat

16.40 PIK3CA testing: from technical aspects to clinical application

Sybille Loibl

17.00 Prognostic signatures to guide treatment decision

Gabriel N. Hortobagyi

17.20 Q&A

17.30 Adjourn

Friday, October 1st

SESSION II –MULTIDISCIPLINARY TUMOR BOARD

Chairperson: Pier Franco Conte, Valentina Guarneri

The speakers will be present at the meeting venue

- 10.00 **Clinical case 1: Omission of RT in elderly patients with low-risk tumor**
Franco Berti
- 10.20 **Clinical case 2: cT1c, cN0 HER2+ tumor: neo vs adjuvant (option to escalate or de-escalate therapy)**
Cristina Falci
- 10.40 **Clinical case 3: Post-neoadjuvant therapy in patients with RD (stressing the concept of RCB and characterization of RD)**
Federica Miglietta
- 11.00 **Clinical case 4: oligometastatic disease**
Grazia Vernaci
- 11.20 **Clinical case 5: Brain mets**
Gaia Griguolo
- 11.40 **Clinical case 6: when to stop active therapy**
Carlo Alberto Giorgi
- 12.00 *Lunch*

SESSION III

Chairpersons: Jacek Jassem, Valentina Guarneri

The speakers will be connected by various countries

- 14.30 **Adjuvant CDK4/6i for HR+ disease: reconciling data from randomized trials**
Valentina Guarneri
- 14.50 **Early BRCAm tumors: PARPi are coming!**
Pier Franco Conte

- 15.10 **Neoadjuvant therapy for early breast cancer:
beyond the pCR dogma**
Pier Franco Conte
- 15.30 **Immunotherapy for early TNBC: hopes and hypes**
Hope Rugo
- 15.50 **Q&A**
- 16.10 **Antibody Drug Conjugates for BC**
Frederik Marmè
- 16.30 **Targeting unconventional pathways in Luminal BC**
Maria Vittoria Dieci
- 16.50 **Treatment algorithm for HR+/HER2- ABC**
Stephen Johnston
- 17.10 **Treatment algorithm for HER2+ ABC**
Sandra Swain
- 17.30 **Treatment algorithm and new options for TN ABC**
Miguel Martin
- 17.50 **Q&A**
- 18.10 **Adjourn**

CME

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-324769): **8 CME points**.

The credit certification for the webinar is subject to:

- Professions/specializations should correspond to those which have been accredited for CME;
- attendance at the 90% of the meeting;
- completion of the meeting evaluation online form;
- completion of the final test (at least 75% of correct answers).
1 attempt admitted.

The test and the meeting evaluation form must be completed within 3 days from the end of the event.

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

Teaching method

The in-class course will take place at the venue specified underneath. Please note that due to COVID mitigation measures, the availability of places for the in-presence course is limited.

The in-class course, with the participation of speakers connected from various countries and local speakers present at the meeting venue, is addressed primarily to Italian participants. The official language of the course is English. No simultaneous translation will be provided.

Directors

Pier Franco Conte

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padova (I)*

Valentina Guarneri

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padova (I)*

Gabriel N. Hortobagyi

*Department of Breast Medical Oncology
The University of Texas -
MD Anderson Cancer Center
Houston (USA)*

Philip Poortmans

*Former president of ESTRO and of ECCO
Department of Radiation Oncology
Iridium Netwerk
University of Antwerp
Wilrijk-Antwerp (B)*

Scientific Committee

Hesham Ahmed Gaballah Elghazaly

*Department of Clinical Oncology
and nuclear medicine
University of Ainshams
Cairo (EG)*

Jacek Jassem

*Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)*

Stephen Johnston

*NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation
Trust & Institute of Cancer Research
London (UK)*

Sibylle Loibl

*German Breast Group
University of Frankfurt (D)*

Eleuterios Mamounas

*Comprehensive Breast Program
MD Anderson Cancer Center Orlando
Orlando (F)*

Miguel Martin

*Medical Oncology Service
Hospital Universitario Gregorio Marañón
Madrid (E)*

Stefania Migliuolo

*Europa Donna Italia
Milan (I)*

Fedro Alessandro Peccatori

*Department of Medical Oncology
European Institute of Oncology (IEO)
Milan (I)*

Aleix Prat

*Medical Oncology Department
Hospital Clinic
Barcelona (E)*

Sandra M. Swain

*Research Development
Georgetown University Medical Center
Washington (USA)*

Speakers

Franco Berti

*Department of Radiation Oncology
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padua (I)*

Pierfranco Conte

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padova (I)*

Maria Vittoria Dieci

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padova (I)*

Cristina Falci

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padua (I)*

Carlo Alberto Giorgi

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padua (I)*

Gaia Griguolo

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padua (I)*

Gabriel N. Hortobagyi

*Department of Breast Medical Oncology
The University of Texas -
MD Anderson Cancer Center
Houston (USA)*

Jacek Jassem

*Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)*

Stephen Johnston

*NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust &
Institute of Cancer Research
London (UK)*

Sibylle Loibl

*German Breast Group
University of Frankfurt (D)*

Eleuterios Mamounas

*Comprehensive Breast Program
MD Anderson Cancer Center Orlando
Orlando (F)*

Frederik Marmè

*National Center for Tumor Diseases (NCT)
University of Heidelberg (DE)*

Miguel Martin

*Medical Oncology Service
Hospital Universitario Gregorio Marañón
Madrid (E)*

Federica Miglietta

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padua (I)*

Shani Paluch-Shimon

*Sharett Institute of Oncology
Hadassah University Hospital
Jerusalem (IL)*

Philip Poortmans

*Former president of ESTRO and of ECCO
Department of Radiation Oncology
Iridium Network
University of Antwerp
Wilrijk-Antwerp (B)*

Aleix Prat

*Medical Oncology Department
Hospital Clinic
Barcelona (E)*

Hope Rugo

*UCSF Carol Franc Buck Breast Care Center
Breast Oncology Clinical Trials Program
San Francisco (USA)*

Sandra M. Swain

*Research Development
Georgetown University Medical Center
Washington (USA)*

Grazia Vernaci

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padua (I)*

Roberto Vettor

*Division of Internal Medicine
University of Padova (I)*

Registration

Meeting venue In-Class Course
Four Points by Sheraton
Corso Argentina, 5
Padova

€ 180,00

€ 100,00 for graduate students and nurses

Online registration at <http://meettheprofessor.accmed.org> **before 20 September**; the application will be completed only after the payment of the registration fee.

CANCELLATION

In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be reimbursed.

Under 40

Free admission is available for a few people “under 40”.

Registration forms will be accepted on a first-come, first-served basis until spaces will be full.

The Organization Secretariat will confirm the registration by email.



Un'azione sostenibile a favore della formazione

Iscrizione gratuita **UNDER 40** fino a esaurimento posti

With the unconditional sponsorship of

With the patronage of

INSTITUTIONS



PATROCINIO
REGIONE DEL VENETO

1222-2022
800
ANNI



UNIVERSITÀ
DEGLI STUDI
DI PADOVA



SCIENTIFIC SOCIETIES





Organizer

ACCADEMIA NAZIONALE
DI MEDICINA



General Manager: Stefania Ledda
www.accmed.org

Information:

<http://meettheprofessor.accmed.org>
Ph. 0039 51 0569163 – 51 6360080
info.bologna@accmed.org

Organizing Partner

Forum Service
Via Martin Piaggio, 17/8
16122 Genova